Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Meet Masoudi: Deputy Counsel Brings Antitrust Experience To FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA Deputy Chief Counsel Gerald Masoudi can be expected to reinforce the agency's aggressive stance toward product liability suits that encroach on its regulatory authority

You may also be interested in...



Once and future Chief Counsel

Gerald Masoudi returns from the Justice Department to become FDA chief counsel/associate general counsel effective Oct. 12. He replaces Sheldon Bradshaw, who left the agency Sept. 12 to join the Washington, D.C. firm Hunton & Williams (1"The Tan Sheet" Sept. 10, 2007, In Brief). The role will be a familiar one for Masoudi, who came to FDA in 2004 as deputy chief counsel and was acting chief counsel for several months before Bradshaw was named to the post (2"The Tan Sheet" April 11, 2005, p. 7). Since 2005, Masoudi has been deputy assistant attorney general in charge of International, Policy and Appellate Matters in the Antitrust Division at the U.S. Department of Justice. Before joining FDA, Masoudi was a partner at Kirkland & Ellis, where his background included antitrust work (3"The Tan Sheet" Nov. 15, 2004, p. 12)...

Once and future Chief Counsel

Gerald Masoudi returns from the Justice Department to become FDA chief counsel/associate general counsel effective Oct. 12. He replaces Sheldon Bradshaw, who left the agency Sept. 12 to join the Washington, D.C. firm Hunton & Williams (1"The Tan Sheet" Sept. 10, 2007, In Brief). The role will be a familiar one for Masoudi, who came to FDA in 2004 as deputy chief counsel and was acting chief counsel for several months before Bradshaw was named to the post (2"The Tan Sheet" April 11, 2005, p. 7). Since 2005, Masoudi has been deputy assistant attorney general in charge of International, Policy and Appellate Matters in the Antitrust Division at the U.S. Department of Justice. Before joining FDA, Masoudi was a partner at Kirkland & Ellis, where his background included antitrust work (3"The Tan Sheet" Nov. 15, 2004, p. 12)...

Once and future Chief Counsel

Gerald Masoudi returns from the Justice Department to become FDA chief counsel/associate general counsel effective Oct. 12. He replaces Sheldon Bradshaw, who left the agency Sept. 12 to join the Washington, D.C. firm Hunton & Williams (1"The Tan Sheet" Sept. 10, 2007, In Brief). The role will be a familiar one for Masoudi, who came to FDA in 2004 as deputy chief counsel and was acting chief counsel for several months before Bradshaw was named to the post (2"The Tan Sheet" April 11, 2005, p. 7). Since 2005, Masoudi has been deputy assistant attorney general in charge of International, Policy and Appellate Matters in the Antitrust Division at the U.S. Department of Justice. Before joining FDA, Masoudi was a partner at Kirkland & Ellis, where his background included antitrust work (3"The Tan Sheet" Nov. 15, 2004, p. 12)...

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel